BACKGROUND: It has been suggested that specific antihypertensive medications (AHT) may either increase or decrease breast cancer risk. METHODS: We studied breast cancer incidence among 49,950 women in North Jutland, Denmark in order to determine if breast cancer risk is associated with specific classes of AHT use. Poisson regression analyses were used to calculate rate ratios for ever or exclusive use of each class of AHT, number of prescriptions for AHT, and years of follow-up. RESULTS: There was no statistically significant association between ever use of any AHT overall (RR = 0.95; 95% CI = 0.81-1.10) or any specific class of AHT (diuretics, beta blockers, calcium channel blockers (CCBs), angiotensin converting enzyme (ACE) inhibitors, and angiotensin II antagonists) and breast cancer. CONCLUSIONS: This study should offer further reassurance to women currently using AHT that their medication use is unlikely related to breast cancer risk.
BACKGROUND: It has been suggested that specific antihypertensive medications (AHT) may either increase or decrease breast cancer risk. METHODS: We studied breast cancer incidence among 49,950 women in North Jutland, Denmark in order to determine if breast cancer risk is associated with specific classes of AHT use. Poisson regression analyses were used to calculate rate ratios for ever or exclusive use of each class of AHT, number of prescriptions for AHT, and years of follow-up. RESULTS: There was no statistically significant association between ever use of any AHT overall (RR = 0.95; 95% CI = 0.81-1.10) or any specific class of AHT (diuretics, beta blockers, calcium channel blockers (CCBs), angiotensin converting enzyme (ACE) inhibitors, and angiotensin II antagonists) and breast cancer. CONCLUSIONS: This study should offer further reassurance to women currently using AHT that their medication use is unlikely related to breast cancer risk.
Authors: Gitte Vrelits Sørensen; Patricia A Ganz; Steven W Cole; Lars A Pedersen; Henrik Toft Sørensen; Deirdre P Cronin-Fenton; Jens Peter Garne; Peer M Christiansen; Timothy L Lash; Thomas P Ahern Journal: J Clin Oncol Date: 2013-05-06 Impact factor: 44.544
Authors: Lu Chen; Jessica Chubak; Denise M Boudreau; William E Barlow; Noel S Weiss; Christopher I Li Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-08-14 Impact factor: 4.254
Authors: Raquel N Rozner; Azael Freites-Martinez; Jerry Shapiro; Eliza B Geer; Shari Goldfarb; Mario E Lacouture Journal: Breast Cancer Res Treat Date: 2018-11-22 Impact factor: 4.872
Authors: Robert W Mathes; Kathleen E Malone; Janet R Daling; Scott Davis; Sylvia M Lucas; Peggy L Porter; Christopher I Li Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-11 Impact factor: 4.254
Authors: Joan A Largent; Leslie Bernstein; Pamela L Horn-Ross; Sarah F Marshall; Susan Neuhausen; Peggy Reynolds; Giske Ursin; Jason A Zell; Argyrios Ziogas; Hoda Anton-Culver Journal: Cancer Causes Control Date: 2010-06-06 Impact factor: 2.506
Authors: Daniel R Rhodes; Bushra Ateeq; Qi Cao; Scott A Tomlins; Rohit Mehra; Bharathi Laxman; Shanker Kalyana-Sundaram; Robert J Lonigro; Beth E Helgeson; Mahaveer S Bhojani; Alnawaz Rehemtulla; Celina G Kleer; Daniel F Hayes; Peter C Lucas; Sooryanarayana Varambally; Arul M Chinnaiyan Journal: Proc Natl Acad Sci U S A Date: 2009-06-01 Impact factor: 11.205
Authors: Christopher I Li; Janet R Daling; Mei-Tzu C Tang; Kara L Haugen; Peggy L Porter; Kathleen E Malone Journal: JAMA Intern Med Date: 2013-09-23 Impact factor: 21.873